Ixaka is a private UK-based cell and gene therapy company with operations in the UK, Spain and France.  The company is focused on the natural power of the body to cure disease.

Our proprietary technologies enhance the inherent therapeutic power of cells by targeting curative cells to the site of disease and by directly modifying cells within the body to improve their therapeutic action.

Ixaka’s technologies – concentrated multi-cell therapies and targeted nano-particles – demonstrate potential for the treatment of a broad range of serious diseases across oncology, cardiovascular, neurological and ocular diseases, and genetic disorders.

Biotechnology

Ixaka

Gilbert Wagener

Eva López

Géraldine SARAGOUSSI

Roxana Tundrea

Victoria García

Karen Miller

Christian Hoyer Millar

The Leadership Team at Ixaka is responsible for steering the strategic vision and operational direction of the company. Comprising key executives such as the CEO and Vice Presidents of Scientific and Technical Operations, the team collaborates to drive innovation in cell and gene therapies, ensuring the effective development and commercialization of proprietary technologies. They focus on fostering a culture of scientific excellence while navigating market opportunities in the treatment of serious diseases.

Leadership Team

Scientific Research and Development

Quality Control and Assurance Team

Leadership Team

About

Team members

Other teams at Ixaka

Scientific Research and Development

Quality Control and Assurance Team